Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
0.8310
+0.0029 (0.35%)
Sep 5, 2025, 9:32 AM - Market open

Company Description

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors.

Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Context Therapeutics Inc.
Context Therapeutics logo
CountryUnited States
Founded2015
IPO DateOct 20, 2021
IndustryBiotechnology
SectorHealthcare
Employees12
CEOMartin Lehr

Contact Details

Address:
2001 Market Street, Suite 3915
Philadelphia, Pennsylvania 19103
United States
Phone267-225-7416
Websitecontexttherapeutics.com

Stock Details

Ticker SymbolCNTX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$5.00
CIK Code0001842952
CUSIP Number21077P108
ISIN NumberUS21077P1084
Employer ID86-3738787
SIC Code2834

Key Executives

NamePosition
Martin A. LehrCo-Founder, President, Chief Executive Officer and Director
Jennifer Minai-AzaryChief Financial Officer and Treasurer
Alex C. Levit Esq., J.D.Chief Legal Officer and Corporate Secretary
Christopher Beck M.B.A.Senior Vice President of Operations
Jeffrey LiebmanAssociate Director of Accounting
Jennifer Dashnau M.B.A., Ph.D.Senior Vice President of Technical Operations
Dr. Karen Chagin M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Sep 2, 20258-KCurrent Report
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 6, 202510-QQuarterly Report
Jun 12, 20258-KCurrent Report
Jun 2, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 9, 2025SCHEDULE 13G/AFiling
May 7, 202510-QQuarterly Report